Characterization Of A Novel Composite Scaffold Consisting Of Acellular Bladder Submucosa Matrix, Polycaprolactone, And Pluronic F127 As A Substance For Bladder Reconstruction

The bladder is an organ susceptible to a variety of congenital anomalies, injuries and disorders. To address the clinical limitations of existing scaffolds, we fabricated a novel scaffold that can be applied to morphological and functional bladder reconstruction. As a first step to prove the benefit of the scaffold, intensive in vitro and in vivo analyses were conducted. The novel composite scaffold was fabricated using polycaprolactone/Pluronic F127 (PCL/F127) and variable proportions (1, 3, 5 and 10wt.%) of porcine acellular bladder submucosa matrix (BSM). Physicochemical properties and biocompatibilities of the scaffolds were characterized. For cell-mediated analysis, upper-urinary-tract-derived urine stem cells were used. Observations of tensile strength, modulus, porosity, cell adhesion, viability and proliferation characteristics of scaffolds indicated that the optimum proportion of BSM in the composite scaffolds was 3 or 5 wt.%. Based on comparison of 3 and 5 wt.% BSM/PCL/F127 scaffolds with respect to degradability, hydrophilicity, surface properties and functional group presence, the 3 wt.% BSM was chosen for in vivo studies. 8 weeks after kidney-subcapsular implantation of the 3 wt.% BSM/PCL/F127 scaffold, cells remained attached to the surface and there was no evidence of teratomas. A BSM content of 3 wt.% was the optimum proportion for fabrication of the neo scaffold. We predict that the 3 wt.% BSM/PCL/F127 composite scaffold could act as an ideal matrix after cystectomy based on its favorable physicochemical properties and biocompatibilities.